For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.
Neon's cancer vaccine makes a decent early showing, but overall survival remain a crucial measure.
Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
Hopes for lumateperone rest on schizophrenia as bipolar data raise questions.
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
Positive data, toxicity, a US FDA delay and the early leaking of information culminate in a green light for the multiple myeloma drug.
Yet another project brought in through business development fails, exposing Sumitomo’s limited pipeline.
Paying $40m up front for a preclinical asset is a bold move, even for the red-hot Nash space, though Boehringer has shelled out here before.